BiotechTube
RegCell

RegCell

Cambridge, United States· Est.
regcellbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

RegCell is a private, pre-clinical stage biotech developing Treg-based cell therapies to restore immune self-tolerance in autoimmune diseases. Founded on the pioneering work of Dr. Shimon Sakaguchi, who discovered Tregs, the company aims to create durable, disease-modifying treatments that avoid the broad immunosuppression of current standards. Led by a seasoned executive team with deep experience in drug development and corporate strategy, RegCell is positioned to advance a novel therapeutic platform in a large and underserved market.

Autoimmune Diseases

Technology Platform

Therapeutic platform based on the ex vivo expansion and potential engineering of regulatory T cells (Tregs) to restore immune tolerance in autoimmune diseases.

Opportunities

The global autoimmune disease market is vast and underserved by therapies that address root causes, offering a multi-billion dollar opportunity for a curative modality.
Success in Treg therapy could enable a paradigm shift from chronic symptom management to durable remission, justifying premium pricing.
The growing validation of cell therapy platforms in oncology creates a favorable regulatory and manufacturing precedent.

Risk Factors

Significant scientific risks include ensuring Treg stability, persistence, and efficacy in a complex disease microenvironment.
The path to market requires overcoming substantial clinical, manufacturing, and regulatory hurdles for a novel cell therapy.
The company faces intense competition from both established immunosuppressive drugs and other novel modalities in development.

Competitive Landscape

RegCell competes in the broad autoimmune space against large pharma with dominant biologic drugs and a growing number of biotechs developing next-gen small molecules, antibodies, and other cell therapies (e.g., CAR-Tregs, TCR-based therapies). Its key differentiation is a foundational focus on natural Treg biology for restoring tolerance, rather than broad immunosuppression or targeting single inflammatory pathways.

More companies in Cell & Gene Therapy →More companies in United States →